Kyron Bio signed a research agreement with Servier focused on Kyron’s programmable glycoprotein platform to precisely control therapeutic protein glycosylation. The deal establishes a collaboration to refine glycosylation patterns for improved biologic stability and function, with Kyron positioning the technology as a solution to a longstanding biopharma manufacturing challenge. The agreement will fund joint research activities and could lead to downstream licensing or development partnerships if Kyron’s glycoengineering claims translate into improved therapeutic profiles.